Background
Methods
Study population
Data collection and measurements
Echocardiography
Statistical analysis
Results
Clinical characteristics
Variables | Control | HT | HT + DM |
---|---|---|---|
N = 4990 |
N = 4462 |
N = 818 | |
Age | 49.9 ± 9.4 | 56.9 ± 10.3*
| 58.3 ± 9.0#†
|
Males, n (%) | 2146 (43.0%) | 2200 (49.3%) | 353 (43.2%)**
|
Han ethnicity, n (%) | 4743 (95.1%) | 4236 (94.9%) | 778 (95.1%) |
Height, cm | 161.0 ± 8.0 | 160.3 ± 8.3*
| 159.7 ± 8.4#
|
Weight, kg | 62.2 ± 10.7 | 65.4 ± 11.5*
| 67.8 ± 11.7#†
|
WC, cm | 79.6 ± 9.2 | 84.3 ± 9.6*
| 87.7 ± 9.3#†
|
BSA, m2 | 1.62 ± 0.17 | 1.66 ± 0.18*
| 1.69 ± 0.19#†
|
BMI, kg/ m2
| 23.94 ± 3.49 | 25.39 ± 3.62*
| 26.49 ± 3.65#†
|
BMI ≥ 30 kg/ m2, n (%) | 237 (4.7%) | 423 (9.5%) | 131 (16.0%)**
|
Current smoke, n (%) | 1761 (35.3%) | 1603 (35.9%) | 231 (28.2%)**
|
Current drinking, n (%) | 1015 (20.3%) | 1114 (25.0%) | 177 (21.6%)**
|
Heart rate, bmp | 76.36 ± 11.66 | 77.95 ± 13.42*
| 85.65 ± 14.99#†
|
SBP, mmHg | 123.70 ± 9.83 | 158.06 ± 18.97*
| 162.11 ± 20.57#†
|
DBP, mmHg | 74.96 ± 7.37 | 88.75 ± 10.85*
| 88.89 ± 11.60#
|
TC, mmol/L | 5.03 ± 1.00 | 5.39 ± 1.09*
| 5.69 ± 1.24#†
|
TG, mmol/L | 1.39 ± 1.20 | 1.69 ± 1.29*
| 2.59 ± 2.62#†
|
LDL-C, mmol/L | 2.76 ± 0.74 | 3.06 ± 0.84*
| 3.23 ± 0.94#†
|
HDL-C, mmol/L | 1.40 ± 0.36 | 1.44 ± 0.41*
| 1.32 ± 0.35#†
|
FPG, mmol/L | 5.42 ± 0.52 | 5.60 ± 0.56*
| 9.30 ± 3.14#†
|
PC, mg/dl | 70.82 ± 12.24 | 72.89 ± 28.58*
| 72.74 ± 19.16#
|
Hemoglobin, g/dl | 136.70 ± 19.56 | 140.46 ± 18.46*
| 141.52 ± 16.23#
|
UA, umol/L | 280.38 ± 80.08 | 300.70 ± 86.40*
| 302.26 ± 91.51#
|
Antihypertensive medication, n (%) | 0.00 | 1195 (26.8%) | 330 (40.3%)**
|
Antidiabetic medication, n (%) | 0.00 | 0.00 | 312 (38.1%)**
|
Echocardiographic parameters comparison
Variables | Control | HT | HT + DM |
---|---|---|---|
N = 4990 |
N = 4462 |
N = 818 | |
IVSd, cm | 0.84 ± 0.15 | 0.92 ± 0.30*
| 0.94 ± 0.25#†
|
LVIDd, cm | 4.64 ± 0.39 | 4.76 ± 0.42*
| 4.76 ± 0.45#
|
LVIDs, cm | 3.05 ± 0.39 | 3.15 ± 0.43*
| 3.16 ± 0.43#
|
PWTd, cm | 0.83 ± 0.29 | 0.89 ± 0.21*
| 0.92 ± 0.28#†
|
LVM, g | 123.00 ± 73.62 | 151.87 ± 94.89*
| 159.60 ± 139.43#†
|
LVMI, g/m2.7
| 35.98 ± 20.67 | 42.49 ± 25.77*
| 45.03 ± 36.37#†
|
RWT | 0.36 ± 0.08 | 0.38 ± 0.09*
| 0.39 ± 0.08#†
|
LVH, n (%) | 369 (7.4%) | 1209 (27.1%) | 293 (35.8%)**
|
AOD, cm | 2.20 ± 0.30 | 2.27 ± 0.30*
| 2.28 ± 0.32#
|
LAD, cm | 3.27 ± 0.36 | 3.44 ± 0.39*
| 3.49 ± 0.40#†
|
LAD/BSA, cm/ m2
| 2.03 ± 0.23 | 2.08 ± 0.26*
| 2.08 ± 0.26#
|
E wave, cm/s | 75.90 ± 19.30 | 70.78 ± 18.90*
| 66.47 ± 18.13#†
|
A wave, cm/s | 70.24 ± 15.64 | 80.22 ± 17.45*
| 86.71 ± 18.37#†
|
E/A | 1.16 ± 1.43 | 1.03 ± 6.55 | 0.82 ± 0.67#
|
LVEDV, ml | 100.35 ± 19.59 | 106.55 ± 22.08*
| 107.01 ± 26.26#
|
LVESV, ml | 37.54 ± 11.80 | 40.67 ± 13.59*
| 40.82 ± 13.60#
|
SV, ml | 62.81 ± 16.07 | 65.88 ± 18.42*
| 66.19 ± 22.79#
|
LVEF, % | 0.62 ± 0.10 | 0.62 ± 0.10*
| 0.62 ± 0.10#
|
FS, % | 0.34 ± 0.07 | 0.34 ± 0.07*
| 0.34 ± 0.08 |
Normal geometry, n (%) | 4346 (87.1%) | 2869 (64.3%) | 445 (54.4%)**
|
Concentric remodeling, n (%) | 275 (5.5%) | 384 (8.6%) | 80 (9.8%)**
|
Concentric hypertrophy, n (%) | 60 (1.2) | 432 (9.7%) | 129 (15.8%)**
|
Eccentric hypertrophy, n (%) | 309 (6.2%) | 777 (17.4%) | 164 (20.0%)**
|
Hypertension with or without diabetes and LV geometry abnormality
Classification | LVH | Concentric remodeling | Concentric hypertrophy | Eccentric hypertrophy | ||||
---|---|---|---|---|---|---|---|---|
OR (95% CI) |
P
| OR (95% CI) |
P
| OR (95% CI) |
P
| OR (95% CI) |
P
| |
Total | ||||||||
Control | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT | 2.81 (2.43–3.26) | <0.001*
| 1.32 (1.09–1.59) | 0.004*
| 4.41 (3.28–5.92) | <0.001*
| 2.24 (1.90–2.64) | <0.001*
|
HT + DM | 3.94 (3.08–5.03) | <0.001*
| 1.23 (0.86–1.75) | 0.248 | 7.20 (4.91–10.55) | <0.001*
| 2.38 (1.80–3.16) | <0.001*
|
HT | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT + DM | 1.40 (1.12–1.75) | 0.003*
| 1.01 (0.72–1.42) | 0.953 | 1.61 (1.22–2.12) | 0.001*
| 1.07 (0.83–1.39) | 0.604 |
Men | ||||||||
Control | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT | 2.93 (2.31–3.72) | <0.001*
| 1.71 (1.27–2.29) | <0.001*
| 4.66 (2.95–7.35) | <0.001*
| 2.27 (1.72–2.98) | <0.001*
|
HT + DM | 4.34 (2.98–6.33) | <0.001*
| 1.83 (1.09–3.05) | 0.022 | 6.67 (3.68–12.10) | <0.001*
| 2.98 (1.90–4.65) | <0.001*
|
HT | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT + DM | 1.41 (0.81–2.17) | 0.153 | 1.07 (0.66–1.74) | 0.777 | 1.42 (0.92–2.19) | 0.116 | 1.25 (0.84–1.87) | 0.274 |
Women | ||||||||
Control | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT | 2.74 (2.26–3.31) | <0.001*
| 1.12 (0.87–1.43) | 0.383*
| 4.11 (2.78–6.08) | <0.001*
| 2.24 (1.82–2.75) | <0.001*
|
HT + DM | 3.68 (2.65–5.10) | <0.001*
| 0.95 (0.58–1.55) | 0.836 | 7.21 (4.35–11.95) | <0.001*
| 2.11 (1.46–3.03) | <0.001*
|
HT | 1.00 | 1.00 | 1.00 | 1.00 | ||||
HT + DM | 1.38 (1.02–1.87) | 0.035*
| 0.96 (0.60–1.55) | 0.865 | 1.71 (1.18–2.45) | 0.004*
| 0.98 (0.70–1.38) | 0.898 |